Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
0.290
+0.040 (16.05%)
At close: Nov 20, 2024, 4:00 PM
0.260
-0.030 (-10.34%)
Pre-market: Nov 21, 2024, 5:35 AM EST
Aptevo Therapeutics Employees
Aptevo Therapeutics had 40 employees as of December 31, 2023. The number of employees decreased by 5 or -11.11% compared to the previous year.
Employees
40
Change (1Y)
-5
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$593,025
Market Cap
5.37M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Biofrontera | 85 |
Genetic Technologies | 55 |
Windtree Therapeutics | 20 |
Galmed Pharmaceuticals | 8 |
Pasithea Therapeutics | 8 |
Chromocell Therapeutics | 8 |
Portage Biotech | 7 |
Aptorum Group | 3 |
APVO News
- 21 hours ago - First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - Accesswire
- 9 days ago - First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial - Accesswire
- 13 days ago - Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - Accesswire
- 2 months ago - Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 2 months ago - Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 3 months ago - Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated - Accesswire
- 3 months ago - Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update - Accesswire
- 5 months ago - Aptevo Therapeutics Announces Closing of $2.75 Million Offering - Accesswire